Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma


Correspondence: G. Asaithambi, Department of Neurology, University of Minnesota, 12-100 PWB, 516 Delaware St., SE, Minneapolis, MN 55455, USA. Tel.: +1 612 626 8221; fax: +1 612 625 7950; e-mail:


What is known and Objective

Posterior reversible encephalopathy syndrome (PRES) can be the result of acute hypertension, eclampsia, renal failure and the use of immunosuppressive or cytotoxic agents. We report a case of PRES as a result of the use of pazopanib, a vascular endothelial growth factor inhibitor used for renal cell carcinoma (RCC).

Case summary

A 76-year-old man treated with RCC develops PRES shortly after the initiation of pazopanib.

What is new and conclusion

There are no known reports of the association between PRES and pazopanib. We postulate that pazopanib can disrupt the normal endothelial function of the brain leading to the development of PRES.